The news database brings together all published information on platforms and products, as well as financial and corporate news.
Join our mailing list.
28 Apr 2025
ADOCIA to Present New Data on AdoShell® at Upcoming Scientific Conferences – Showcasing Potential Curative Treatment for Type 1 Diabetes
17 Apr 2025
ADOCIA Announces Full Year 2024 Financial Results and Provides a Corporate and Financial Update
26 Feb 2025
ADOCIA Announces the Successful Completion of a €9.7 Million Private Placement, Extending its Cash Runway to Q2 2026
22 Jan 2025
ADOCIA Announces Half-Year Report on Adocia’s Liquidity Agreement with Kepler Capital Markets
12 Dec 2024
ADOCIA and Tonghua Dongbao Announce the Final Dosing in a Phase 3 Clinical Study of BioChaperone® Lispro, Milestone Associated with a $10 Million Payment
Olivier Soula – Bourse et Valeurs, Lyon Pole Bourse 2024 (FR)
15 Oct 2024
ADOCIA announces patenting stable combinations of GLP-1 and amylin analogs for the treatment of obesity and diabetes using its BioChaperone® platform
19 Jul 2024
ADOCIA Announces Half year report on Adocia’s liquidity agreement with Kepler Capital Markets
Web Conference – BioChaperone Combo – July 2024 (FR)
10 Jul 2024
ADOCIA Announces that Tonghua Dongbao is Discontinuing one of the two Partnership Programs: BioChaperone® Combo
18 Jun 2024
ADOCIA Announces Three Presentations at the American Diabetes Association 84th Scientific Sessions
Interview Olivier Soula – La France de Demain, Radio Classique – May 2024 (FR)
23 May 2024
ADOCIA Announces its Annual Shareholders’ Meeting to be Held on June 13th, 2024 in Paris
Olivier Soula – LSX World Congress – April 2024
24 Apr 2024
ADOCIA Announces Full Year 2023 Financial Results and Provides a Corporate and Financial Update
Interview Olivier Soula – Le Journal des Biotechs – March 2024 (FR)
21 Mar 2024
ADOCIA Announces a €2 Million Fundraising from its two Main Shareholders and a Member of its Management, and the Signature of an Equity Financing Line with Vester Finance
BIO-Europe Spring 2024: Interview with Jérémy Benattar
Web-conference – 4th Quarter 2023 Financial Results (FR)
Join our mailing list. Subscribe